Table 11. Viability of HepG2 Cell Line Determined by Viability Cell Assaysa after 48 h of Treatment with Compounds 56c, 61b, 67b, 67c, 67e, 69a, 69b, 69c, 69e, 79a, 79e, 81a, and 81e and Their Selectivity Indicesb.
| IC50 (μM) | viability at 30 μM (%) | SIc | (MIC for M.tb.) | |
|---|---|---|---|---|
| 56c | >30 | 92 ± 4 | >15 | (2) |
| 61b | >30 | 88 ± 6 | >7.5 | (4) |
| 67b | 10.18 ± 1.01 | 33 ± 4 | 20.4 | (0.5) |
| 67c | 23.28 ± 1.37 | 51 ± 16 | 46.6 | (0.5) |
| 67e | 12.47 ± 1.09 | 35 ± 5 | 12.5 | (1) |
| 69a | 8.3 ± 0.92 | 32 ± 9 | 8.3 | (1) |
| 69b | 5.94 ± 0.77 | 17 ± 1 | 5.9 | (1) |
| 69c | 13.41 ± 1.13 | 29 ± 15 | 13.4 | (1) |
| 69e | 10.16 ± 1.01 | 30 ± 12 | 10.2 | (1) |
| 79a | >30 | 93 ± 4 | >30 | (1) |
| 79e | >30 | 54 ± 2 | >30 | (1) |
| 81a | >30 | 98 ± 5 | >15 | (2) |
| 81e | >30 | 55 ± 5 | >15 | (2) |
a
CellTiter96 assay.
b
Vehicle-treated control viability was set to 100%. SDS-treated cell viability was set to 0%.
c
Selectivity index (SI) was calculated using the formula: SI = (IC50 for HepG2)/(MIC for M.tb).